Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 283

1.

AMPKα1 confers survival advantage of colorectal cancer cells under metabolic stress by promoting redox balance through the regulation of glutathione reductase phosphorylation.

Wang YN, Lu YX, Liu J, Jin Y, Bi HC, Zhao Q, Liu ZX, Li YQ, Hu JJ, Sheng H, Jiang YM, Zhang C, Tian F, Chen Y, Pan ZZ, Chen G, Zeng ZL, Liu KY, Ogasawara M, Yun JP, Ju HQ, Feng JX, Xie D, Gao S, Jia WH, Kopetz S, Xu RH, Wang F.

Oncogene. 2019 Sep 17. doi: 10.1038/s41388-019-1004-2. [Epub ahead of print]

PMID:
31530934
2.

Expanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutations.

Dumbrava EI, Brusco L, Daniels M, Wathoo C, Shaw K, Lu K, Zheng X, Strong L, Litton J, Arun B, Eterovic AK, Routbort M, Patel K, Qi Y, Piha-Paul S, Subbiah V, Hong D, Rodon J, Kopetz S, Mendelsohn J, Mills GB, Chen K, Meric-Bernstam F.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00143. Epub 2019 Apr 11.

PMID:
31517177
3.

Current and Future Horizons of Patient-Derived Xenograft Models in Colorectal Cancer Translational Research.

Inoue A, Deem AK, Kopetz S, Heffernan TP, Draetta GF, Carugo A.

Cancers (Basel). 2019 Sep 6;11(9). pii: E1321. doi: 10.3390/cancers11091321. Review.

4.

Correction: A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory.

Arango NP, Brusco L, Shaw KRM, Chen K, Eterovic AK, Holla V, Johnson A, Litzenburger B, Khotskaya YB, Sanchez N, Bailey A, Zheng X, Horombe C, Kopetz S, Farhangfar CJ, Routbort M, Broaddus R, Bernstam EV, Mendelsohn J, Mills GB, Meric-Bernstam F.

Oncotarget. 2019 Aug 27;10(50):5254. doi: 10.18632/oncotarget.27176. eCollection 2019 Aug 27.

5.

Non-invasive genotyping of metastatic colorectal cancer using circulating cell free DNA.

Shi X, Duose DY, Mehrotra M, Harmon MA, Hu P, Wistuba II, Kopetz S, Luthra R.

Cancer Genet. 2019 Sep;237:82-89. doi: 10.1016/j.cancergen.2019.06.004. Epub 2019 Jun 12.

PMID:
31447070
6.

Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018.

Loree JM, Anand S, Dasari A, Unger JM, Gothwal A, Ellis LM, Varadhachary G, Kopetz S, Overman MJ, Raghav K.

JAMA Oncol. 2019 Aug 15:e191870. doi: 10.1001/jamaoncol.2019.1870. [Epub ahead of print]

PMID:
31415071
7.

Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine.

Batth IS, Mitra A, Manier S, Ghobrial IM, Menter D, Kopetz S, Li S.

Ann Oncol. 2019 Aug 13. pii: mdz218. doi: 10.1093/annonc/mdz218. [Epub ahead of print] No abstract available.

PMID:
31406996
8.

Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma.

Korphaisarn K, Morris V, Davis JS, Overman MJ, Fogelman DR, Kee BK, Dasari A, Raghav KPS, Shureiqi I, Trupti M, Wolff RA, Eng C, Menter DG, Hamilton S, Kopetz S.

Br J Cancer. 2019 Sep;121(6):505-510. doi: 10.1038/s41416-019-0548-9. Epub 2019 Aug 13.

PMID:
31406299
9.

Development and Application of Duplex Sequencing Strategy for Cell-Free DNA-Based Longitudinal Monitoring of Stage IV Colorectal Cancer.

Mallampati S, Zalles S, Duose DY, Hu PC, Medeiros LJ, Wistuba II, Kopetz S, Luthra R.

J Mol Diagn. 2019 Aug 8. pii: S1525-1578(19)30351-4. doi: 10.1016/j.jmoldx.2019.06.008. [Epub ahead of print]

PMID:
31401123
10.

Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma.

Veeranki OL, Tong Z, Dokey R, Mejia A, Zhang J, Qiao Y, Singh PK, Katkhuda R, Mino B, Tailor R, Canales JR, Bassett R, Ajani J, Wu JY, Kopetz S, Blum M, Hofstetter W, Tetzlaff M, Krishnan S, Lin SH, Maru D.

Oncotarget. 2019 Jul 23;10(45):4703-4718. doi: 10.18632/oncotarget.27095. eCollection 2019 Jul 23.

11.

Targeting CDK9 and MCL-1 by a new CDK9/p-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma.

Tong Z, Mejia A, Veeranki O, Verma A, Correa AM, Dokey R, Patel V, Solis LM, Mino B, Kathkuda R, Rodriguez-Canales J, Lin SH, Krishnan S, Kopetz S, Blum M, Ajani JA, Hofstetter WL, Maru DM.

Ther Adv Med Oncol. 2019 Jul 25;11:1758835919864850. doi: 10.1177/1758835919864850. eCollection 2019.

12.

Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel.

Willis J, Lefterova MI, Artyomenko A, Kasi PM, Nakamura Y, Mody K, Catenacci DVT, Fakih M, Barbacioru C, Zhao J, Sikora M, Fairclough SR, Lee H, Kim KM, Kim ST, Kim J, Gavino D, Benavides M, Peled N, Nguyen T, Cusnir M, Eskander RN, Azzi G, Yoshino T, Banks KC, Raymond VM, Lanman RB, Chudova DI, Talasaz A, Kopetz S, Lee J, Odegaard JI.

Clin Cancer Res. 2019 Aug 4. doi: 10.1158/1078-0432.CCR-19-1324. [Epub ahead of print]

PMID:
31383735
13.

How liquid biopsies can change clinical practice in oncology.

Siravegna G, Mussolin B, Venesio T, Marsoni S, Seoane J, Dive C, Papadopoulos N, Kopetz S, Corcoran RB, Siu LL, Bardelli A.

Ann Oncol. 2019 Aug 2. pii: mdz227. doi: 10.1093/annonc/mdz227. [Epub ahead of print]

PMID:
31373349
14.

CTC analysis: an update on technological progress.

Batth IS, Mitra A, Rood S, Kopetz S, Menter D, Li S.

Transl Res. 2019 Jul 11. pii: S1931-5244(19)30136-7. doi: 10.1016/j.trsl.2019.07.003. [Epub ahead of print] Review.

PMID:
31348892
15.

Genetic profiling as a clinical tool in advanced parathyroid carcinoma.

Kutahyalioglu M, Nguyen HT, Kwatampora L, Clarke C, Silva A, Ibrahim E, Waguespack SG, Cabanillas ME, Jimenez C, Hu MI, Sherman SI, Kopetz S, Broaddus R, Dadu R, Wanland K, Williams M, Zafereo M, Perrier N, Busaidy NL.

J Cancer Res Clin Oncol. 2019 Aug;145(8):1977-1986. doi: 10.1007/s00432-019-02945-9. Epub 2019 Jul 15.

PMID:
31309300
16.

Biomarker-guided therapy for colorectal cancer: strength in complexity.

Sveen A, Kopetz S, Lothe RA.

Nat Rev Clin Oncol. 2019 Jul 9. doi: 10.1038/s41571-019-0241-1. [Epub ahead of print] Review.

PMID:
31289352
17.

Mechanisms of Innate and Acquired Resistance to Anti-EGFR therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies.

Parseghian CM, Napolitano S, Loree JM, Kopetz S.

Clin Cancer Res. 2019 Jul 1. doi: 10.1158/1078-0432.CCR-19-0823. [Epub ahead of print] Review.

PMID:
31263029
18.

Mutation Status of RAS, TP53, and SMAD4 is Superior to Mutation Status of RAS Alone for Predicting Prognosis after Resection of Colorectal Liver Metastases.

Kawaguchi Y, Kopetz S, Newhook TE, De Bellis M, Chun YS, Tzeng CD, Aloia TA, Vauthey JN.

Clin Cancer Res. 2019 Jun 20. doi: 10.1158/1078-0432.CCR-19-0863. [Epub ahead of print]

PMID:
31221662
19.

Evolving Strategies for the Management of BRAF-Mutant Metastatic Colorectal Cancer.

Lee HM, Morris V, Napolitano S, Kopetz S.

Oncology (Williston Park). 2019 Jun 19;33(6):206-11. Review.

20.

Can Circulating Tumor DNA in Early-Stage Colorectal Cancer Be More Than a Prognostic Biomarker?

Morris V, Dasari A, Kopetz S.

JAMA Oncol. 2019 May 9. doi: 10.1001/jamaoncol.2019.0503. [Epub ahead of print] No abstract available.

PMID:
31070713
21.

Conditional Recurrence-Free Survival after Resection of Colorectal Liver Metastases: Persistent Deleterious Association with RAS and TP53 Co-Mutation.

Kawaguchi Y, Lillemoe HA, Panettieri E, Chun YS, Tzeng CD, Aloia TA, Kopetz S, Vauthey JN.

J Am Coll Surg. 2019 Sep;229(3):286-294.e1. doi: 10.1016/j.jamcollsurg.2019.04.027. Epub 2019 May 2.

PMID:
31054911
22.

KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer.

Liao W, Overman MJ, Boutin AT, Shang X, Zhao D, Dey P, Li J, Wang G, Lan Z, Li J, Tang M, Jiang S, Ma X, Chen P, Katkhuda R, Korphaisarn K, Chakravarti D, Chang A, Spring DJ, Chang Q, Zhang J, Maru DM, Maeda DY, Zebala JA, Kopetz S, Wang YA, DePinho RA.

Cancer Cell. 2019 Apr 15;35(4):559-572.e7. doi: 10.1016/j.ccell.2019.02.008. Epub 2019 Mar 21.

PMID:
30905761
23.

Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study.

Van Cutsem E, Huijberts S, Grothey A, Yaeger R, Cuyle PJ, Elez E, Fakih M, Montagut C, Peeters M, Yoshino T, Wasan H, Desai J, Ciardiello F, Gollerkeri A, Christy-Bittel J, Maharry K, Sandor V, Schellens JHM, Kopetz S, Tabernero J.

J Clin Oncol. 2019 Jun 10;37(17):1460-1469. doi: 10.1200/JCO.18.02459. Epub 2019 Mar 20.

PMID:
30892987
24.

Clinical and molecular characterization of early-onset colorectal cancer.

Willauer AN, Liu Y, Pereira AAL, Lam M, Morris JS, Raghav KPS, Morris VK, Menter D, Broaddus R, Meric-Bernstam F, Hayes-Jordan A, Huh W, Overman MJ, Kopetz S, Loree JM.

Cancer. 2019 Jun 15;125(12):2002-2010. doi: 10.1002/cncr.31994. Epub 2019 Mar 11.

PMID:
30854646
25.

Ongoing and future directions in the management of metastatic colorectal cancer: Update on clinical trials.

Advani S, Kopetz S.

J Surg Oncol. 2019 Apr;119(5):642-652. doi: 10.1002/jso.25441. Epub 2019 Mar 10. Review.

PMID:
30852840
26.

Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.

Capasso A, Lang J, Pitts TM, Jordan KR, Lieu CH, Davis SL, Diamond JR, Kopetz S, Barbee J, Peterson J, Freed BM, Yacob BW, Bagby SM, Messersmith WA, Slansky JE, Pelanda R, Eckhardt SG.

J Immunother Cancer. 2019 Feb 8;7(1):37. doi: 10.1186/s40425-019-0518-z.

27.

Prevalence of recurrent oncogenic fusion in mismatch repair-deficient colorectal carcinoma with hypermethylated MLH1 and wild-type BRAF and KRAS.

Wang J, Yi Y, Xiao Y, Dong L, Liang L, Teng L, Ying JM, Lu T, Liu Y, Guan Y, Pang J, Zhou L, Lu J, Zhang Z, Liu X, Liang X, Zeng X, Yi X, Zhou W, Xia X, Yang L, Zhang J, Kopetz S, Futreal PA, Wu H, Liang Z.

Mod Pathol. 2019 Jul;32(7):1053-1064. doi: 10.1038/s41379-019-0212-1. Epub 2019 Feb 5.

PMID:
30723297
28.

Back to the Colorectal Cancer Consensus Molecular Subtype Future.

Menter DG, Davis JS, Broom BM, Overman MJ, Morris J, Kopetz S.

Curr Gastroenterol Rep. 2019 Jan 30;21(2):5. doi: 10.1007/s11894-019-0674-9. Review.

29.

Refining the Use of Adjuvant Oxaliplatin in Clinical Stage II or III Rectal Adenocarcinoma.

Margalit O, Mamtani R, Kopetz S, Yang YX, Lawrence YR, Abu-Gazala S, Reiss KA, Golan T, Halpern N, Aderka D, Giantonio B, Shacham-Shmueli E, Boursi B.

Oncologist. 2019 Aug;24(8):e671-e676. doi: 10.1634/theoncologist.2018-0333. Epub 2019 Jan 29.

PMID:
30696723
30.

Real-Time Interrogation of Aspirin Reactivity, Biochemistry, and Biodistribution by Hyperpolarized Magnetic Resonance Spectroscopy.

Zacharias NM, Ornelas A, Lee J, Hu J, Davis JS, Uddin N, Pudakalakatti S, Menter DG, Karam JA, Wood CG, Hawk ET, Kopetz S, Vilar E, Bhattacharya PK, Millward SW.

Angew Chem Int Ed Engl. 2019 Mar 22;58(13):4179-4183. doi: 10.1002/anie.201812759. Epub 2019 Feb 20.

31.

Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer.

Varkaris A, Katsiampoura A, Davis JS, Shah N, Lam M, Frias RL, Ivan C, Shimizu M, Morris J, Menter D, Overman M, Tran H, Heymach J, Chun YS, Vauthey JN, Calin G, Kopetz S.

Br J Cancer. 2019 Feb;120(3):340-345. doi: 10.1038/s41416-018-0360-y. Epub 2019 Jan 14.

PMID:
30636774
32.

New therapies and insights into the changing landscape of colorectal cancer.

Kopetz S.

Nat Rev Gastroenterol Hepatol. 2019 Feb;16(2):79-80. doi: 10.1038/s41575-018-0100-z. Review. No abstract available.

PMID:
30575801
33.

Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge.

Parseghian CM, Loree JM, Morris VK, Liu X, Clifton KK, Napolitano S, Henry JT, Pereira AA, Vilar E, Johnson B, Kee B, Raghav K, Dasari A, Wu J, Garg N, Raymond VM, Banks KC, Talasaz AA, Lanman RB, Strickler JH, Hong DS, Corcoran RB, Overman MJ, Kopetz S.

Ann Oncol. 2019 Feb 1;30(2):243-249. doi: 10.1093/annonc/mdy509.

PMID:
30462160
34.

Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2.

Chang K, Willis JA, Reumers J, Taggart MW, San Lucas FA, Thirumurthi S, Kanth P, Delker DA, Hagedorn CH, Lynch PM, Ellis LM, Hawk ET, Scheet PA, Kopetz S, Arts J, Guinney J, Dienstmann R, Vilar E.

Ann Oncol. 2018 Oct 1;29(10):2061-2067. doi: 10.1093/annonc/mdy337.

PMID:
30412224
35.

Circulating Tumor DNA-Defined Minimal Residual Disease in Solid Tumors: Opportunities to Accelerate the Development of Adjuvant Therapies.

Dasari A, Grothey A, Kopetz S.

J Clin Oncol. 2018 Oct 30:JCO2018789032. doi: 10.1200/JCO.2018.78.9032. [Epub ahead of print] No abstract available.

PMID:
30376428
36.

TMEM9 promotes intestinal tumorigenesis through vacuolar-ATPase-activated Wnt/β-catenin signalling.

Jung YS, Jun S, Kim MJ, Lee SH, Suh HN, Lien EM, Jung HY, Lee S, Zhang J, Yang JI, Ji H, Wu JY, Wang W, Miller RK, Chen J, McCrea PD, Kopetz S, Park JI.

Nat Cell Biol. 2018 Dec;20(12):1421-1433. doi: 10.1038/s41556-018-0219-8. Epub 2018 Oct 29.

37.

DNA Sequencing of Small Bowel Adenocarcinomas Identifies Targetable Recurrent Mutations in the ERBB2 Signaling Pathway.

Adam L, San Lucas FA, Fowler R, Yu Y, Wu W, Liu Y, Wang H, Menter D, Tetzlaff MT, Ensor J Jr, Manyam G, Arold ST, Huff C, Kopetz S, Scheet P, Overman MJ.

Clin Cancer Res. 2019 Jan 15;25(2):641-651. doi: 10.1158/1078-0432.CCR-18-1480. Epub 2018 Oct 23.

PMID:
30352910
38.

Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics.

Khan M, Loree JM, Advani SM, Ning J, Li W, Pereira AAL, Lam M, Raghav K, Morris VK, Broaddus R, Maru D, Overman MJ, Kopetz S.

Clin Colorectal Cancer. 2018 Dec;17(4):e699-e709. doi: 10.1016/j.clcc.2018.07.005. Epub 2018 Jul 17.

39.

Loss of muscle mass during preoperative chemotherapy as a prognosticator for poor survival in patients with colorectal liver metastases.

Okuno M, Goumard C, Kopetz S, Vega EA, Joechle K, Mizuno T, Tzeng CD, Chun YS, Lee JE, Vauthey JN, Aloia TA, Conrad C.

Surgery. 2019 Feb;165(2):329-336. doi: 10.1016/j.surg.2018.07.031. Epub 2018 Sep 6.

PMID:
30197278
40.

Bioactive lipid metabolism in platelet "first responder" and cancer biology.

Kanikarla-Marie P, Kopetz S, Hawk ET, Millward SW, Sood AK, Gresele P, Overman M, Honn K, Menter DG.

Cancer Metastasis Rev. 2018 Sep;37(2-3):439-454. doi: 10.1007/s10555-018-9755-8. Review.

PMID:
30112590
41.

Clinical, Pathological, and Molecular Characteristics of CpG Island Methylator Phenotype in Colorectal Cancer: A Systematic Review and Meta-analysis.

Advani SM, Advani P, DeSantis SM, Brown D, VonVille HM, Lam M, Loree JM, Mehrvarz Sarshekeh A, Bressler J, Lopez DS, Daniel CR, Swartz MD, Kopetz S.

Transl Oncol. 2018 Oct;11(5):1188-1201. doi: 10.1016/j.tranon.2018.07.008. Epub 2018 Jul 30.

42.

Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer.

Overman MJ, Adam L, Raghav K, Wang J, Kee B, Fogelman D, Eng C, Vilar E, Shroff R, Dasari A, Wolff R, Morris J, Karunasena E, Pisanic TR, Azad N, Kopetz S.

Ann Oncol. 2019 Mar 1;30(3):495. doi: 10.1093/annonc/mdy221. No abstract available.

43.

Phase II study of DFP-10917, a deoxycytidine analog, given by 14-day continuous intravenous infusion for chemotherapy-refractory advanced colorectal cancer.

Mehrvarz Sarshekeh A, Xiong HQ, Iizuka K, Hochster HS, Kopetz S.

Invest New Drugs. 2018 Oct;36(5):895-902. doi: 10.1007/s10637-018-0615-8. Epub 2018 Jun 13.

PMID:
29948357
44.

Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group.

Goey KKH, Sørbye H, Glimelius B, Adams RA, André T, Arnold D, Berlin JD, Bodoky G, de Gramont A, Díaz-Rubio E, Eng C, Falcone A, Grothey A, Heinemann V, Hochster HS, Kaplan RS, Kopetz S, Labianca R, Lieu CH, Meropol NJ, Price TJ, Schilsky RL, Schmoll HJ, Shacham-Shmueli E, Shi Q, Sobrero AF, Souglakos J, Van Cutsem E, Zalcberg J, van Oijen MGH, Punt CJA, Koopman M.

Eur J Cancer. 2018 Sep;100:35-45. doi: 10.1016/j.ejca.2018.05.010. Epub 2018 Jun 22.

PMID:
29936065
45.

How should BRAF V600E-mutated colorectal cancer be treated?

Kopetz S.

Clin Adv Hematol Oncol. 2018 May;16(5):333-335. No abstract available.

PMID:
29851929
46.

RAS Mutation is Associated with Unsalvageable Recurrence Following Hepatectomy for Colorectal Cancer Liver Metastases.

Okuno M, Goumard C, Kopetz S, Vega EA, Joechle K, Mizuno T, Omichi K, Tzeng CD, Chun YS, Vauthey JN, Conrad C.

Ann Surg Oncol. 2018 Aug;25(8):2457-2466. doi: 10.1245/s10434-018-6517-3. Epub 2018 May 21.

PMID:
29786130
47.

Platelet Metabolism and Other Targeted Drugs; Potential Impact on Immunotherapy.

Kanikarla-Marie P, Lam M, Sorokin AV, Overman MJ, Kopetz S, Menter DG.

Front Oncol. 2018 Apr 20;8:107. doi: 10.3389/fonc.2018.00107. eCollection 2018. Review.

48.

Untying the gordion knot of targeting MET in cancer.

Raghav K, Bailey AM, Loree JM, Kopetz S, Holla V, Yap TA, Wang F, Chen K, Salgia R, Hong D.

Cancer Treat Rev. 2018 May;66:95-103. doi: 10.1016/j.ctrv.2018.04.008. Epub 2018 Apr 26. Review.

PMID:
29730462
49.

Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer.

Loree JM, Bailey AM, Johnson AM, Yu Y, Wu W, Bristow CA, Davis JS, Shaw KR, Broaddus R, Banks KC, Lanman RB, Meric-Bernstam F, Overman MJ, Kopetz S, Raghav K.

J Natl Cancer Inst. 2018 Dec 1;110(12):1409-1417. doi: 10.1093/jnci/djy067.

50.

Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome.

Chang K, Taggart MW, Reyes-Uribe L, Borras E, Riquelme E, Barnett RM, Leoni G, San Lucas FA, Catanese MT, Mori F, Diodoro MG, You YN, Hawk ET, Roszik J, Scheet P, Kopetz S, Nicosia A, Scarselli E, Lynch PM, McAllister F, Vilar E.

JAMA Oncol. 2018 Aug 1;4(8):1085-1092. doi: 10.1001/jamaoncol.2018.1482.

Supplemental Content

Loading ...
Support Center